All In Biotech

Drug Trial Radar · NCT05499013

Study to Assess SLN124 in Patients With Polycythemia Vera

Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera

Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

69

Actual

Start

Jan 26, 2023

Primary completion

Sep 2026

Study completion Mar 2030

Sponsor

Lead sponsor
Silence Therapeutics plcIndustry
Sponsor type
Industry
First posted
Aug 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response of SLN124.

Conditions

  • Polycythemia Vera

Interventions

  • SLN124Drug

    SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA).

  • PlaceboDrug

    sodium chloride, solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Incidence of treatment-emergent adverse events (AEs)Time frame: Day 239
  2. Phase 1: Assessment of the number of phlebotomies at intervalsTime frame: 6 months prior to dosing to Day 239
  3. Phase 2: Proportion of patients who achieve response between week 18 and week 36 (placebo controlled double blind phase)Time frame: 18 to 36 weeks

Locations

28 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Hammond, Louisiana

  • Research Site

    Buffalo, New York

  • Research Site

    New York, New York

  • Research Site

    Columbus, Ohio

  • Research Site

    Huntsville, Texas

  • Research Site

    Benowa, Australia

  • Research Site

    Hobart, Australia

  • Research Site

    Kurralta Park, Australia

  • Research Site 2

    Melbourne, Australia

  • Research Site

    Melbourne, Australia

  • Linear Clinical Research

    Nedlands, Australia

  • Research Site

    Richmond, Australia

  • Research Site 2

    Plovdiv, Bulgaria

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Toronto, Canada

  • Research Site

    Freiburg im Breisgau, Germany

  • Research Site

    Hanover, Germany

  • Research Site

    Alessandria, Italy

  • Research Site

    Meldola, Italy

  • Research Site

    Johor Bahru, Malaysia

  • Research Site

    Kuala Terengganu, Malaysia

  • Research Site

    Kuantan, Malaysia

  • Research Site

    Kuching, Malaysia

  • Research Site

    Gdansk, Poland

  • Research Site

    Katowice, Poland

  • Research Site

    Lublin, Poland

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.